Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
Contact Us

$0.00 0 items

Amneal-Web Banner-FINAL-2X

Stanton Mehr April 14, 2026

Published by Stanton Mehr

View all posts by Stanton Mehr

Published April 14, 2026

Post navigation

Previous Post Amneal-Web Banner-FINAL-2X

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search for:

Recent Posts

Sunshine Lake Pharma and Lanexa Biologics Get Their First FDA Biosimilar Approval June 23, 2026
Alvotech Submits First Entyvio Biosimilar Application to FDA June 8, 2026
How Comfortable Are Neurologists With Biosimilar Prescribing? June 3, 2026
The Effect of MFP on Enbrel Sales, and Biosimilar Implications May 28, 2026
What Have I Got Against the Biosimilar Interchangeability Designation? Much. May 19, 2026
First US Approval for a Golimumab Biosimilar: Immgolis and Immgolis Intri to Launch by End of 2026 May 18, 2026
CVS Caremark Drops Stelara Coverage in Favor of Biosimilars May 15, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

The Evolution of the Biosimilars Market
The Implications of the Freefall in Ranibizumab ASPs
Samsung Bioepis Manufacturer Profile June 2026 Update
When Will a Biosimilar Version of Xolair® be Available?
Biosimilar Approval Status
CVS Caremark Drops Stelara Coverage in Favor of Biosimilars
Fewer Stelara Biosimilar Makers Are Offering High-WAC Pricing
Market Share vs. ASP: Do Oncology Biosimilar Trends Make Sense?
Amgen Manufacturer Profile FINAL
Real-World Evidence Says This Formulation Difference May Be a Nonissue for Adalimumab Biosimilars

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.